No Data
No Data
Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now
BofA Securities Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $14
Bank of America Securities Sticks to Their Hold Rating for Vir Biotechnology (VIR)
Vir Biotechnology Down Over 14%, on Pace for Largest Percent Decrease Since July 2023 -- Data Talk
Vir Biotechnology Is Maintained at Outperform by Leerink Partners
Vir Biotechnology Analyst Ratings